The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.
CHAD BRAY, NY Times: Health
Mon, 01/22/2018 - 5:43am
The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant’s portfolio as it faces falling sales for its diabetes drug, Lantus.